This study is testing a new treatment called HTR2 T Cells for metastatic breast cancer that has a protein called HER2. These special immune cells (T cells) are designed to fight cancer. Researchers want to find the safest dose of HTR2 T Cells, understand their side effects, and see how well they work against HER2-positive breast cancer. You might be able to join if you are 18-80 years old, have metastatic or locally advanced HER2-positive breast cancer, and your cancer has continued to grow after at least one standard treatment. The main goal is to see how many people experience serious side effects within four weeks of getting the treatment. The study's current status is unclear, and it plans to enroll 27 participants.

Study design

This is an interventional study with a planned enrollment of 27 participants. It is testing different dose levels of HTR2 T Cells.

What's involved

Your T cells will be collected from your blood, modified, and then given back to you as a single infusion. You may receive Tylenol and Benadryl before the infusion.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for safety is measured at 4 weeks after the first infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.